CIK 0000907654 · Non-accelerated filer<br>Smaller reporting company
Oruka Therapeutics, Inc.
Sign in to watch- Ticker
- ORKA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 363855489
- Phone
- 650-606-7910
- Business address
- 855 OAK GROVE AVE., SUITE 100, MENLO PARK, CA, 94025
- Former names
- ARCA biopharma, Inc., NUVELO INC, HYSEQ INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $20,653,308
- in 17 filings, $20.2M under 10b5-1 plans
Net −$20,653,308. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Klein Lawrence Otto −$11.6M Chief Executive Officer sold 12% of stake
- Agarwal Arjun −$2.8M Senior Vice President, Finance sold 68% of stake
- Goncalves Joana −$2.0M Chief Medical Officer sold 41% of stake
- BALL KRISTINE M −$1.9M Director sold 100% of stake
- Quinlan Paul T −$1.7M General Counsel sold 40% of stake
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-11-02 | Klein Lawrence Otto Chief Executive Officer | Sale 10b5-1 | −15,036 | $95.64 | $1.4M | 926,626 |
| 2026-11-02 | Klein Lawrence Otto Chief Executive Officer | Sale 10b5-1 | −2,442 | $96.70 | $236K | 924,184 |
| 2026-11-02 | Klein Lawrence Otto Chief Executive Officer | Sale 10b5-1 | −756 | $97.45 | $74K | 923,428 |
| 2026-11-02 | Klein Lawrence Otto Chief Executive Officer | Sale 10b5-1 | −300 | $98.40 | $30K | 923,128 |
| 2026-11-02 | Klein Lawrence Otto Chief Executive Officer | Option exercise · Employee Warrant (right to buy) 10b5-1 | −25,000 | 1,503,513 | ||
| 2026-10-20 | Quinlan Paul T General Counsel | Option exercise 10b5-1 | +9,000 | $7.80 | $70K | 38,995 |
| 2026-10-20 | Quinlan Paul T General Counsel | Sale 10b5-1 | −400 | $74.90 | $30K | 38,595 |
| 2026-10-20 | Quinlan Paul T General Counsel | Sale 10b5-1 | −500 | $76.12 | $38K | 38,095 |
| 2026-10-20 | Quinlan Paul T General Counsel | Sale 10b5-1 | −1,000 | $77.21 | $77K | 37,095 |
| 2026-10-20 | Quinlan Paul T General Counsel | Sale 10b5-1 | −4,100 | $78.79 | $323K | 32,995 |
| 2026-10-20 | Quinlan Paul T General Counsel | Sale 10b5-1 | −3,000 | $79.49 | $238K | 29,995 |
| 2026-10-20 | Quinlan Paul T General Counsel | Option exercise · Employee Warrant (right to buy) 10b5-1 | −9,000 | 70,996 | ||
| 2026-10-15 | Goncalves Joana Chief Medical Officer | Option exercise 10b5-1 | +3,500 | $6.84 | $24K | 35,271 |
| 2026-10-15 | Goncalves Joana Chief Medical Officer | Option exercise 10b5-1 | +3,500 | $7.80 | $27K | 38,771 |
| 2026-10-15 | Goncalves Joana Chief Medical Officer | Sale 10b5-1 | −2,853 | $73.89 | $211K | 35,918 |
| 2026-10-15 | Goncalves Joana Chief Medical Officer | Sale 10b5-1 | −1,847 | $74.69 | $138K | 34,071 |
| 2026-10-15 | Goncalves Joana Chief Medical Officer | Sale 10b5-1 | −1,400 | $75.48 | $106K | 32,671 |
| 2026-10-15 | Goncalves Joana Chief Medical Officer | Sale 10b5-1 | −700 | $76.67 | $54K | 31,971 |
| 2026-10-15 | Goncalves Joana Chief Medical Officer | Sale 10b5-1 | −200 | $77.71 | $16K | 31,771 |
| 2026-10-15 | Goncalves Joana Chief Medical Officer | Option exercise · Employee Stock Option (right to buy) 10b5-1 | −3,500 | 190,063 |
Page 2 of 18 · 346 trades